Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3971667 | 0.95 | PTGS2 (0.77) | PTGS2ALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL830784 | 0.94 | PTGS2 (0.75) | PTGS2ALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL8485548 | 0.87 | PTGS2 (0.65) | PTGS2ALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL831162 | 0.86 | PTGS2 (0.65) | PTGS2ALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL11605368 | 0.85 | PTPN7 (0.69) | PTGS2ALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL8832017 | 0.84 | GAA (0.66) | PTGS2ALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL656776 | 0.84 | PTGS2 (0.66) | PTGS2ALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL3026910 | 0.84 | PTGS2 (0.62) | PTGS2ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL2116437 | 0.84 | PTGS2 (0.66) | PTGS2ALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL8060294 | 0.83 | PTGS2 (0.61) | PTGS2ALDH1A1MAPTPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12110278-B2 | Selective JAK2 pseudokinase ligands and methods of use | YALE UNIVERSITY (US) | 2024-10-08 | — | — | US | disclosed |
| US-20220112166-A1 | Selective JAK2 Pseudokinase Ligands and Methods of Use | YALE UNIVERSITY | 2022-04-14 | — | — | US | disclosed |
| US-20220112166-A1 | Selective JAK2 Pseudokinase Ligands and Methods of Use | YALE UNIVERSITY | 2022-04-14 | — | — | US | disclosed |
| US-RE45548-E1 | Functionalized drugs and polymers derived therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2015-06-09 | — | — | US | disclosed |
| US-RE45548-E1 | Functionalized drugs and polymers derived therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2015-06-09 | — | — | US | disclosed |
| US-8846845-B2 | Bioabsorbable and biocompatible polyurethanes and polyamides for medical devices | BEZWADA BIOMEDICAL, LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846845-B2 | Bioabsorbable and biocompatible polyurethanes and polyamides for medical devices | BEZWADA BIOMEDICAL, LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-8802892-B2 | Functionalized phenolic compounds and polymers therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802892-B2 | Functionalized phenolic compounds and polymers therefrom | BEZWADA BIOMEDICAL, LLC (US) | 2014-08-12 | — | — | US | disclosed |
| EP-2298235-B1 | Bioabsorbable and biocompatible polyurethanes and polyamides for medical devices | BEZWADA BIOMEDICAL LLC (US) | 2013-11-06 | — | — | EP | disclosed |
| CN-1157288-A | Benzimidazole derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 1997-08-20 | — | — | CN | disclosed |
| CN-1148492-A | Treatment for arteriosclerosis and vitiligoidea | SANKYO CO (JP) | 1997-04-30 | — | — | CN | disclosed |
| US-5624935-A | ANTIDIABETIC AGENTS, HYPOGLYCEMIC AGENTS OR ANTILIPEMIC AGENTS | SANKYO COMPANY, LIMITED | 1997-04-29 | — | — | US | disclosed |
| EP-0753298-A1 | Synergistic combination comprising an insulin sensitizer and a HMG-CoA reductase inhibitor for treating arteriosclerosis | SANKYO COMPANY LIMITED (JP) | 1997-01-15 | — | — | EP | disclosed |
| EP-0745600-A1 | Benzimidazole derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1996-12-04 | — | — | EP | disclosed |
| WO-1996020173-A1 | PIPERAZINE DERIVATIVES, MEDICAMENTS CONTAINING THE SAME, THEIR USE AND PROCESS FOR PREPARING THE SAME | DR. KARL THOMAE GMBH (DE) | 1996-07-04 | — | — | WO | disclosed |
| EP-0718287-A2 | Piperazine derivatives, medicaments containing them, their use, and processes for their preparation | Dr. Karl Thomae GmbH (DE) | 1996-06-26 | — | — | EP | disclosed |
| EP-0711768-A1 | BENZIMIDAZOLE DERIVATIVE | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1996-05-15 | — | — | EP | disclosed |
| CN-1118781-A | Heterocyclic compound with activity against diabetes and preparation and application of same | MITSUTAKA CO LTD (JP) | 1996-03-20 | — | — | CN | disclosed |
| EP-0676398-A2 | Heterocyclic compounds having anti-diabetic activity, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1995-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12110278-B2 | Selective JAK2 pseudokinase ligands and methods of use | JAK2, JAK1, MCL1 | PTGS2 341/4885ALDH1A1 3690/4885MAPT 4871/4885 |
| US-20220112166-A1 | Selective JAK2 Pseudokinase Ligands and Methods of Use | JAK2, JAK1, MCL1 | PTGS2 341/4885ALDH1A1 3690/4885MAPT 4871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.